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Abstract
Aims: Newer-generation everolimus-eluting stents (EES) have been shown to improve clinical outcomes 
compared with early-generation sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) in patients under-
going percutaneous coronary intervention (PCI). Whether this benefit is maintained among patients with 
saphenous vein graft (SVG) disease remains controversial.
Methods and results: We assessed cumulative incidence rates (CIR) per 100 patient years after inverse 
probability of treatment weighting to compare clinical outcomes. The pre-specified primary endpoint was the 
composite of cardiac death, myocardial infarction (MI), and target vessel revascularisation (TVR). Out of 
12,339 consecutively treated patients, 288 patients (5.7%) underwent PCI of at least one SVG lesion with 
EES (n=127), SES (n=103) or PES (n=58). Up to four years, CIR of the primary endpoint were 58.7 for EES, 
45.2 for SES and 45.6 for PES with similar adjusted risks between groups (EES vs. SES; HR 0.94, 95% CI: 
0.55-1.60, EES vs. PES; HR 1.07, 95% CI: 0.60-1.91). Adjusted risks showed no significant differences 
between stent types for cardiac death, MI and TVR.
Conclusions: Among patients undergoing PCI for SVG lesions, newer-generation EES have similar safety 
and efficacy to early-generation SES and PES during long-term follow-up to four years.
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Abbreviations
ARC Academic Research Consortium
BMS bare metal stent(s)
CIR cumulative incidence rates
DES drug-eluting stent(s)
EES everolimus-eluting stent(s)
HR hazard ratio
IQR interquartile range
MACE major adverse cardiac events
MI myocardial infarction
NSTEMI non-ST-segment elevation myocardial infarction
PCI percutaneous coronary intervention
PES paclitaxel-eluting stent(s)
SD standard deviation
SES sirolimus-eluting stent(s)
ST stent thrombosis
STEMI ST-segment elevation myocardial infarction
SVG saphenous vein graft
TVR target vessel revascularisation
ULN upper limit of normal
Introduction
Approximately 3-6% of percutaneous coronary interventions (PCI) are 
performed among patients with saphenous vein graft (SVG) disease1, 
and this represents the most important revascularisation option for 
patients with graft failure. PCI of SVG lesions is characterised by high 
rates of restenosis and periprocedural myocardial infarction (MI) com-
pared with revascularisation of native coronary arteries. Compared 
with bare metal stents (BMS), drug-eluting stents (DES) have been 
shown to reduce the risk of repeat revascularisation by 50%, related to 
a potent inhibition of neointimal tissue proliferation2 without differ-
ences in terms of cardiac death or MI in the largest randomised trial 
performed to date3,4. However, early-generation DES releasing siroli-
mus (SES) or paclitaxel (PES) from durable polymers were used in two 
thirds of patients enrolled in this study1, and little is known regarding 
the outcomes of newer-generation DES among patients with SVG dis-
ease. The newer-generation everolimus-eluting stent (EES) is a thin-
strut, cobalt-chromium alloy stent, which is coated with a durable, 
fluorinated co-polymer releasing a reduced dose of everolimus com-
pared to the dose used with SES5. EES have been shown to improve 
efficacy and safety compared with early-generation PES6-8 through two 
years and to provide similar efficacy but improved safety compared 
with early-generation SES9,10 in a wide range of patients and lesions. 
However, it is unknown whether the favourable results with the use of 
newer-generation EES remain sustained among patients undergoing 
PCI for SVG disease. We therefore investigated the long-term clinical 
outcomes of patients undergoing PCI of SVG lesions with the use of 
EES compared with SES and PES in a large-scale registry.
Methods
PATIENT POPULATION
The Bern-Rotterdam registry evaluates clinical outcomes of 
patients treated with the unrestricted use of DES enrolled at Bern 
University Hospital, Bern, Switzerland, and the Thoraxcenter, 
Erasmus Medical Center, Rotterdam, The Netherlands.
Primary results with focus on stent thrombosis have been 
reported previously6,7,11. In the Dutch institution, SES had been used 
as a default strategy for PCI as part of the Rapamycin-Eluting Stent 
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) regis-
try. From the first quarter of 2003, PES became commercially avail-
able and replaced SES as default device and became part of the 
TAXUS Stent Evaluated At Rotterdam Cardiology Hospital 
(T-SEARCH) registry. EES (XIENCE V®; Abbott Vascular, Santa 
Clara, CA, USA, or PROMUS®; Boston Scientific, Natick, MA, 
USA) had been used as a default strategy for PCI as part of the 
XIENCE Stent Evaluated At Rotterdam Cardiology Hospital 
(X-SEARCH) registry since March 1, 2007, until the end of this 
study period. In the Swiss institution, EES had been used since 
November 1, 2006, and were implanted on a daily basis alternating 
with biolimus-eluting stents and zotarolimus-eluting stents. SES 
had been used since April, 2002, and PES since March, 2003. 
Individual patients who had been treated with more than one type of 
DES were excluded from the current registry. The study was 
approved by the local ethics committee at both institutions and was 
in accordance with the Declaration of Helsinki. Written informed 
consent was obtained from all patients.
DATA COLLECTION
All patients were actively followed for major adverse cardiac 
events using patient administered postal questionnaires including 
questions on rehospitalisation and major adverse cardiac events. 
This was complemented by a search of hospital databases at the two 
institutions. In Bern, the last follow-up took place from February 1, 
2007, onwards for patients who had undergone implantation of SES 
or PES and from February 1, 2010, onwards for patients with EES. 
In Rotterdam, the last follow-up took place from July 1, 2005, 
onwards for patients with PES, July 1, 2006, for patients with SES, 
and April 1, 2010, onwards for patients with EES, respectively. For 
patients with a suspected event, relevant medical records, discharge 
letters, and coronary angiography documentation were systemati-
cally collected. All suspected clinical events were adjudicated by 
local cardiologists affiliated with the two institutions, whereas all 
ST events were adjudicated by an independent clinical events com-
mittee whose members were unaware of the type of stent implanted. 
Baseline clinical and procedural characteristics and all follow-up 
data were entered into a dedicated database, held at an academic 
clinical trials unit (CTU Bern, Bern University Hospital, Bern, 
Switzerland) responsible for central data audits and maintenance of 
the database.
PROCEDURES
EES were available in diameters from 2.25 to 4.0 mm and in lengths 
from 8 to 28 mm; SES were available in diameters from 2.25 to 
3.5 mm and in lengths from 8 to 33 mm, and PES were available in 
diameters from 2.25 to 4.0 mm and in lengths from 8 to 32 mm. 
The procedure and treatment including peri- and post-procedural 
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medication regimen were performed according to current practice 
guidelines. All patients irrespective of stent type received a loading 
dose of clopidogrel 300 mg to 600 mg during or immediately after 
the procedure and were prescribed aspirin once daily lifelong. In 
the Dutch institution, clopidogrel was administered to patients with 
SES for at least three months, and for at least six months if patients 
had received three or more stents, the total stent length was >36 mm, 
or a chronic total occlusion or bifurcation was treated. Dutch 
patients treated with EES were prescribed clopidogrel for 
12 months. In the Swiss institution, all patients were prescribed 
clopidogrel for a duration of at least 12 months irrespective of stent 
type. The use of glycoprotein IIb/IIIa antagonists and distal protec-
tion devices was left at the discretion of the operator.
DEFINITIONS
The primary endpoint of this study was major adverse cardiac events 
(MACE) defined as the composite of cardiac death, MI, and target 
vessel revascularisation up to four years. The definition of cardiac 
death included any death due to immediate cardiac cause, procedure-
related deaths, unwitnessed death and death of unknown cause. The 
diagnosis of MI was based on an elevation in CK to more than twice 
the upper limit of normal (ULN) and an elevation of CK-MB to more 
than three times ULN in the presence of ischaemic symptoms or 
ischaemic ECG changes. Target vessel revascularisation (TVR) was 
defined as any repeat percutaneous intervention or surgical bypass of 
any segment within the entire major coronary vessel proximal and 
distal to the target lesion, including upstream and downstream 
branches and the target lesion itself. Target lesion revascularisation 
(TLR) was defined as a repeated revascularisation due to a stenosis 
within the stent or within the 5 mm borders proximal or distal to the 
stent. A 12-lead electrocardiogram was obtained prior to the proce-
dure and within 24 hours after PCI. Additional ECGs were obtained 
in case of recurrent signs or symptoms of ischaemia. Acute coronary 
syndrome was defined as acute myocardial ischaemia based on clini-
cal symptoms, electrocardiographic changes, and elevation of car-
diac biomarkers, and encompassed an acute ST-segment (STEMI) 
and non-ST-segment elevation myocardial infarction (NSTEMI) and 
unstable angina. Definitions of hypertension, hyperlipidaemia and 
renal dysfunction were reported previously7,11. Stent thrombosis was 
defined according to the Academic Research Consortium (ARC)8,9.
STATISTICAL ANALYSIS
Baseline clinical and procedural characteristics of the three stent 
types are presented as counts and percentages for dichotomous 
variables and as mean and standard deviation (SD) for continuous 
variables. Pearson’s chi-square test and Student’s t-test were used 
for comparing dichotomous and continuous variables, respectively. 
Cumulative incidence rates (CIR) per 100 patient years were calcu-
lated for each endpoint, defined as the number of new events occur-
ring during a specific time period divided by the total number of 
patient years observed. In contrast to crude percentages, CIR take 
into account differences in follow-up duration between different 
stent types. Propensity scores for receiving EES were estimated for 
each centre by the use of a logit model including age, gender and 
pre-treatment variables associated with stent selection at p<0.10 
(i.e., family history of coronary artery disease, acute coronary syn-
drome and cardiogenic shock for both centres; body mass index and 
left ventricular ejection fraction as additional variables for Bern; 
arterial hypertension, smoking, diabetes and hyperlipidaemia as 
additional variables for Rotterdam). Propensity scores were used to 
derive inverse probability of treatment weights, with the inverse of 
propensity score as analytical weights in EES-treated patients and 
the inverse of 1 minus the propensity score among early-generation 
DES-treated patients. Comparisons between stent types were per-
formed with a Cox proportional hazards model, crude and adjusted 
using inverse probability of treatment weighting. All statistical 
analyses were performed using STATA release 11.1 (StataCorp, 
College Station, TX, USA). All p-values are two-sided.
Results
Between April 16, 2002, and March 31, 2009, 12,339 consecutive 
patients underwent treatment with the unrestricted use of EES 
(n=4,212), SES (n=3,819) and PES (n=4,308). Out of this cohort, 
288 patients (5.7%) (177 [61.5%] enrolled at Bern University Hospi-
tal, and 111 [38.5%] included at Thoraxcenter, Rotterdam) under-
went PCI of at least one SVG lesion with the use of EES among 
127 patients, SES among 103 patients, and PES among 58 patients. 
Baseline clinical characteristics for all three stent types are summa-
rised in Table 1. Patients treated with EES compared with those 
treated with either SES or PES more frequently had diabetes. 
Patients treated with EES were more frequently hypertensive com-
pared to those treated with PES, and more frequently had dyslipi-
daemia, renal failure and presented with an acute coronary 
syndrome than SES-treated patients. Table 2 shows procedural 
characteristics, which were balanced among the three treatment 
groups with the exception of a larger stent diameter in lesions treated 
with EES compared with those treated with SES. The use of glyco-
protein IIb/IIIa antagonists, aspirin, and proton pump inhibitors was 
more frequent among EES compared with PES-treated patients.
Clinical outcome
The median follow-up duration among surviving patients complet-
ing the last follow-up was 2.5 years in patients treated with EES 
(interquartile range: IQR 1.9 to 3.2 years), four years in patients 
treated with SES (IQR 3.0 to 4.0 years), and 3.5 years in patients 
treated with PES (IQR 2.3 to 4.0 years) with an accumulated 144, 
266, and 302 patient years, respectively.
Clinical outcomes up to four years are summarised in Table 3 
and Table 4.
Up to four years, incidence rates per 100 patient years for the pri-
mary endpoint MACE were similar among patients treated with EES 
(58.7%), SES (45.2%, adjusted HR 0.94, 95% CI: 0.55-1.60) and 
PES (45.6%, adjusted HR 1.07, 95% CI: 0.60.-1.91) in adjusted anal-
yses (Table 3 and Table 4, Figure 1). Similarly, there was no differ-
ence in the risk of cardiac death (EES vs. SES adjusted HR 1.18, 95% 
CI: 0.49-2.84, EES vs. PES adjusted HR 0.81, 95% CI: 0.30-2.17), 
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Table 1. Baseline clinical characteristics.
Stent type p-value
EES (A) SES (B) PES (C) A vs. B A vs. C
Number of patients 127 103 58
Age (yr) 69.2 (9.6) 67.5 (10.5) 68.3 (8.8) 0.19 0.54
Male gender 104 (81.9) 86 (83.5) 53 (91.4) 0.75 0.09
Body mass index (kg/m2) 27.7 (3.6) 27.2 (3.7) 27.4 (3.8) 0.27 0.64
Hypertension 89 (70.1) 67 (65.0) 28 (48.3) 0.42 0.004
Family history of CAD 44 (34.6) 33 (32.0) 18 (31) 0.68 0.63
Smoking at baseline 43 (33.9) 47 (45.6) 24 (41.4) 0.07 0.32
Dyslipidaemia 101 (79.5) 69 (67.0) 39 (67.2) 0.031 0.07
Diabetes mellitus 46 (36.2) 18 (17.5) 11 (19) 0.002 0.018
Renal failure (GFR <60 ml/min)* 12 (21.4) 11 (13.4) 8 (20.5) 0.21 0.91
Renal failure (creatinine >150 μmol/l)* 4 (7.1) 0 (0) 2 (5.1) 0.014 0.69
Left ventricular ejection fraction, <30% 3 (6.3) 6 (7.8) 3 (8.8) 0.75 0.66
Acute coronary syndrome 74 (58.3) 39 (37.9) 26 (44.8) 0.002 0.09
Unstable angina/non-ST-elevation MI 57 (77.0) 34 (87.2) 23 (88.5) 0.20 0.21
ST-elevation MI 17 (23.0) 5 (12.8) 3 (11.5) – –
Cardiogenic shock 1 (0.8) 0 (0) 0 (0) 0.37 0.50
Values are n (%) or mean±SD. *data only available in Bern patients. Comparisons between groups among dichotomous variables were performed using 
Pearson’s chi-square test and Student’s t-test for continuous variables.  CAD: coronary artery disease; EES: everolimus-eluting stent; GFR: glomerular 
filtration rate; MI: myocardial infarction; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent
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Figure 1. Cumulative event curves for the primary endpoint of major adverse cardiac events (MACE) (A), cardiac death (B), myocardial 
infarction (MI) (C), and target vessel revascularisation (TVR) (D) up to 48 months. *Crude hazard ratio is shown, as adjusted model did not 
converge. EES: everolimus-eluting stents; PES: paclitaxel-eluting stents; SES: sirolimus-eluting stents 
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MI (EES vs. SES adjusted HR 0.84, 95% CI: 0.25-2.83, EES vs. PES 
crude HR 4.14, 95% CI: 0.51-33.44), and TVR (EES vs. SES adjusted 
HR 0.92, 95% CI: 0.49-1.75, EES vs. PES adjusted HR 1.17, 95% 
CI: 0.58-2.36) in adjusted analyses. The incidence rates per 100 
patient years for definite ST and definite or probable ST showed no 
differences among stent types at any time point (Table 5).
Table 2. Baseline procedural characteristics.
Stent type p-value
EES (A) SES (B) PES (C) A vs. B A vs. C
Total (n) 127 103 58
Multivessel treatment 20 (15.7) 22 (21.4) 11 (19.0) 0.27 0.59
Number of vessels treated per patient 1.2 (0.4) 1.2 (0.6) 1.2 (0.4) 0.29 0.80
Number of lesions treated per patient 1.4 (0.6) 1.4 (0.8) 1.3 (0.5) 0.68 0.34
1 lesion 40 (71.4) 55 (67.1) 30 (76.9) – –
2 lesions 11 (19.6) 19 (23.2) 8 (20.5) – –
3 lesions 5 (8.9) 4 (4.9) 1 (2.6) – –
Number of stents per patient 1.9 (1.1) 2.1 (1.2) 1.8 (1.0) 0.33 0.41
Average stent diameter 3.2 (0.5) 3 (0.3) 3.2 (0.5) 0.0002 0.35
Total stent length per patient 32.4 (23.0) 37.6 (24.4) 33.1 (26.5) 0.10 0.86
Glycoprotein IIb/IIIa antagonist 26 (20.5) 14 (13.6) 2 (3.4) 0.17 0.003
Medication at discharge
Aspirin 123 (100) 99 (98.0) 56 (96.6) 0.12 0.038
Clopidogrel 123 (100) 99 (99.0) 57 (98.3) 0.27 0.14
Oral anticoagulation 7 (5.7) 6 (5.9) 7 (12.1) 0.94 0.13
Beta-blocker 37 (66.1) 54 (67.5) 25 (64.1) 0.86 0.84
ACE inhibitor 23 (41.1) 39 (48.8) 18 (46.2) 0.38 0.62
AT II inhibitor 10 (17.9) 17 (21.3) 4 (10.3) 0.63 0.30
Calcium antagonist 12 (21.4) 18 (22.5) 11 (28.2) 0.88 0.45
Statin 52 (92.9) 69 (86.3) 33 (84.6) 0.23 0.20
Oral antidiabetic 8 (14.3) 12 (15.0) 2 (5.1) 0.91 0.15
Insulin 5 (8.9) 3 (3.8) 5 (12.8) 0.21 0.54
Diuretics 18 (32.1) 20 (25.0) 13 (33.3) 0.36 0.90
Proton pump inhibitor 21 (37.5) 20 (25.0) 6 (15.4) 0.12 0.019
Values are n (%) or mean±SD. Comparisons between groups among dichotomous variables were performed using Pearson’s chi-square test and Student’s 
t-test for continuous variables. Number of patients on discharge medication is based on the number of patients alive at discharge. EES: everolimus-
eluting stent; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent
Table 3. Clinical outcome at 1 year.
Stent type Adjusted analysis
EES (A) SES (B) PES (C)
A vs. B A vs. C
HR (95% CI) p-value HR (95% CI) p-value
Number of patients 127 103 58
All-cause death 13 (10.4) 3 (2.9) 4 (7.0) 3.71 (1.06-13.03)* 0.04* 1.50 (0.49-4.60)* 0.48*
Cardiac death 7 (5.8) 3 (2.9) 3 (5.3) 1.18 (0.20-7.05) 0.85 0.89 (0.21-3.81) 0.87
MI 4 (3.4) 3 (2.9) 1 (1.8) 0.70 (0.13-3.73) 0.68 0.47 (0.03-7.40) 0.59
TLR 7 (6.1) 11 (10.8) 3 (5.6) 0.43 (0.12-1.50) 0.18 0.73 (0.17-3.16) 0.68
TVR 10 (8.6) 17 (16.7) 5 (9.3) 0.34 (0.10-1.13) 0.08 0.55 (0.17-1.80) 0.32
Cardiac death/MI 11 (9.0) 5 (4.9) 4 (7.0) 1.46 (0.43-5.01) 0.55 0.93 (0.26-3.33) 0.91
Cardiac death/MI/TLR 15 (12.3) 15 (14.6) 7 (12.3) 0.71 (0.30-1.70) 0.45 0.75 (0.28-1.99) 0.56
Cardiac death/MI/TVR 17 (13.9) 21 (20.4) 9 (15.8) 0.53 (0.23-1.23) 0.14 0.63 (0.26-1.50) 0.29
Clinical outcome numbers are expressed as counts and incidence rates per 100 patient years. Adjusted risk ratios were calculated using inverse 
probability of treatment weights as analytical weighting in Cox proportional hazard models. *Crude rates are shown, as adjusted model did not converge. 
CI: confidence interval; EES: everolimus-eluting stent; HR: hazard ratio; MI: myocardial infarction; PES: paclitaxel-eluting stent; SES: sirolimus-eluting 
stent; TLR: target lesion revascularisation; TVR: target vessel revascularisation
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The duration of dual antiplatelet therapy differed between the 
two institutions. In order to analyse potential site-specific differ-
ences in outcomes comparing EES with early-generation DES, we 
performed a sensitivity analysis for the primary outcome and found 
hazards to be similar for both institutions regarding the primary 
endpoint (Bern EES vs. early-generation DES: HR 0.94, 95% CI: 
0.55-1.60, p=0.82; Rotterdam EES vs. early-generation DES: HR 
1.07, 95% CI: 0.60-1.01, p=0.82).
Discussion
This is the first report comparing newer-generation EES with early-
generation SES and PES during long-term follow-up among 
patients undergoing PCI for SVG disease. The main findings of our 
study are: 1) the use of EES resulted in similar safety and efficacy 
compared to the use of early-generation SES and PES among 
patients with SVG lesions; 2) event rates for restenosis and recur-
rent ischaemia were exceedingly high during follow-up through 
four years regardless of the type of DES implanted.
Limited data are available on the treatment of SVG lesions with 
coronary artery stents.
A comparison of DES with BMS in SVG lesions in a total of 
5,543 patients followed for at least one year yielded similar results 
to those observed in other patient populations, namely a substantial 
improvement in the need for repeat revascularisation of the target 
vessel without differences in terms of MI or stent thrombosis. 
Differences in cardiac death were not recorded when taking into 
account only randomised trials12. However, conflicting results were 
observed among the few studies investigating outcomes beyond 
one year. The randomised Extended Duration of the Reduction of 
Restenosis In Saphenous vein grafts with Cypher stent (DELAYED 
RRISC) study suggested an increased risk of cardiac death and 
numerically lower rates of MI with SES compared with BMS as 
well as a loss of the initially observed lower risk of TVR during 
long-term follow-up. Conversely, the long-term results of the 
Stenting of Saphenous Vein Grafts (SOS) trial suggested a similar 
risk of cardiac death but a lower risk of MI as well as sustained effi-
cacy in terms of repeat revascularisation among PES compared 
with BMS-treated patients with SVG disease during long-term 
follow-up.
Newer-generation DES have been designed to improve upon 
the limitations of early-generation DES by reducing stent strut 
thickness, increasing the biocompatibility of polymers and modi-
fying drug content. Several randomised clinical trials as well as 
large-scale registries confirmed improved safety and efficacy of 
Table 5. Definite or definite/probable stent thrombosis up to 4 years.
Stent type Adjusted analysis
EES (A) SES (B) PES (C)
A vs. B A vs. C
HR (95% CI) p-value HR (95% CI) p-value
Number of patients 127 103 58
Definite stent thrombosis 4 (4.0) 3 (3.1) 1 (2.2) 1.28 (0.29-5.74)* 0.74* 0.88 (0.10-8.03) 0.91
Definite or probable stent thrombosis 9 (10.1) 9 (9.5) 3 (5.7) 0.79 (0.24-2.61) 0.69 0.90 (0.22-3.64) 0.89
Clinical outcome numbers are expressed as counts and incidence rates per 100 patient years. Adjusted risk ratios were calculated using inverse probability 
of treatment weights as analytical weighting in Cox proportional hazard models stratified by centre. *Crude rates are shown, as adjusted model did not 
converge. CI: confidence interval; HR: hazard ratio; EES: everolimus-eluting stent; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent
Table 4. Clinical outcome up to 4 years.
Stent type Adjusted analysis
EES (A) SES (B) PES (C)
A vs. B A vs. C
HR (95% CI) p-value HR (95% CI) p-value
Number of patients 127 103 58
All-cause death 22 (21.5) 19 (19.5) 11 (24.8) 1.01 (0.52-1.97) 0.98 0.94 (0.41-2.14) 0.88
Cardiac death 14 (15.3) 12 (13.2) 9 (21.8) 1.18 (0.49-2.84) 0.71 0.81 (0.30-2.17) 0.67
MI 8 (9.1) 8 (8.5) 1 (1.8) 0.84 (0.25-2.83) 0.77 4.14 (0.51-33.44)* 0.18*
TLR 19 (25.8) 26 (27.6) 6 (12.6) 0.73 (0.35-1.53) 0.40 1.58 (0.57-4.35) 0.38
TVR 28 (52.0) 34 (35.5) 14 (31.0) 0.92 (0.49-1.75) 0.81 1.17 (0.58-2.36) 0.67
Cardiac death/MI 21 (21.8) 19 (20.3) 10 (23.2) 1.01 (0.48-2.10) 0.99 0.95 (0.38-2.41) 0.92
Cardiac death/MI/TLR 34 (37.9) 36 (37.6) 15 (32.0) 0.87 (0.49-1.56) 0.65 1.16 (0.59-2.31) 0.66
Cardiac death/MI/TVR¶ 40 (58.7) 44 (45.2) 22 (45.6) 0.94 (0.55-1.60) 0.82 1.07 (0.60-1.91) 0.81
¶Composite primary endpoint. Clinical outcome numbers are expressed as counts and incidence rates per 100 patient years. Adjusted risk ratios were 
calculated using inverse probability of treatment weights as analytical weighting in Cox proportional hazard models. *Crude rates are shown, as adjusted 
model did not converge. CI: confidence interval; EES: everolimus-eluting stent; HR: hazard ratio; MI: myocardial infarction; PES: paclitaxel-eluting 
stent; SES: sirolimus-eluting stent; TLR: target lesion revascularisation; TVR: target vessel revascularisation
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newer-generation EES compared with PES and SES in a wide 
range of patient and lesion subsets. To date, only one study has 
compared early-generation DES with a newer-generation stent 
releasing sirolimus from a biodegradable polymer among patients 
undergoing treatment of SVG lesions and observed no difference in 
terms of the primary endpoint including cardiac death, MI, and 
repeat revascularisation13. As it relates to long-term results, no data 
are available at this point in time.
Our study is the first to compare newer-generation EES with 
early-generation SES and PES among patients undergoing PCI of 
SVG lesions during long-term follow-up through four years, and is 
of particular interest due to the unselected, consecutive patient pop-
ulation undergoing PCI with the unrestricted use of DES. Similar to 
outcomes in ISAR-CABG, outcomes for the primary endpoint and 
its individual components were similar for newer-generation DES 
compared with early-generation SES and PES. Even when consid-
ering device-specific endpoints such as cardiac death, MI and TLR 
as well as stent thrombosis, no differences were noted among these 
devices throughout the entire follow-up period.
Irrespective of stent type, adverse events were much more fre-
quent among patients undergoing PCI of SVG lesions compared to 
those undergoing PCI of native coronary arteries. Specifically, rates 
of MACE at four years in the present study (46%) were similar to 
those reported among PES-treated patients in the randomised 
Stenting of Saphenous Vein Grafts (SOS) trial at 35 months of fol-
low-up (54%)14. Similarly, in the Extended Duration of the 
Reduction of Restenosis In Saphenous vein grafts with Cypher 
stent (DELAYED RRISC) study15, rates of MACE amounted to 
58% among SES-treated patients at a median follow-up of 
32 months. These figures contrast with rates of MACE in the range 
of 20% among unselected patients enrolled in all-comers studies 
with the predominant treatment of native coronary artery lesions16-18. 
Of note, clinical outcomes were driven by high rates of death, reste-
nosis of the target lesion as well as disease progression within the 
target vessel, reflecting the advanced stage of coronary artery dis-
ease in this patient population.
Potential explanations for the lack of benefit with newer-genera-
tion EES compared with early-generation DES in the specific sub-
set of SVG lesions may have been the small patient population. 
However, considering the high event rates and the long-term fol-
low-up, hazards would be expected to favour EES, assuming simi-
lar benefits in terms of relative risk reduction observed in pivotal 
trials and all-comer patient populations. Differences between SVG 
lesions and native coronary arteries in terms of periprocedural treat-
ment characteristics, atherosclerotic disease burden as well as the 
interaction with revascularisation by means of drug-eluting stents 
may be of relevance. Brilakis and colleagues reported an increased 
risk for in-hospital mortality among patients undergoing PCI for 
treatment of SVG compared to native coronary artery lesions (HR 
1.22, 95% CI: 1.12-1.32, p<0.001). This was related to differences 
in patient and lesion risk profile and a higher incidence of acute 
complications such as no reflow19. SVG failure remote from the 
stented lesion (TVR without TLR) occurs in 30-50% of all repeat 
revascularisation procedures. This proportion is certainly higher 
compared with lesions involving native coronary arteries20,21, sug-
gesting that non-stented disease progression remains an important 
adverse event among patients with SVG disease. Although rates of 
target lesion revascularisation during the first year in the present 
study were very much comparable to those observed following 
treatment of native coronary artery lesions, recurrent ischaemia 
related to the stented segment became increasingly apparent at 
a later time, suggesting a considerable lack of long-term efficacy. 
Specifically, annual rates of TLR between the first and fourth year 
of follow-up were 50 to 70% higher compared with annual rates 
previously reported in the context of native coronary artery dis-
ease16. Therefore, SVG lesions continue to represent an important 
lesion subset with inadequate efficacy following the use of newer-
generation DES.
Pathological analyses and experimental animal models have con-
tributed to our understanding of accelerated atherosclerosis in SVG 
lesions22. Mechanical stress induced by a substantial change in 
haemodynamics from a venous to an arterial circulation has been 
identified as an important source of saphenous vein graft wall thick-
ening, largely related to gene expression of adhesion molecules, 
which evoke inflammatory processes and signal pathways resulting 
in proliferative cell growth. Neointimal formation is followed by 
macrophage infiltration and eventually necrotic core formation, 
resulting in vulnerable plaque formation. Stent implantation of 
SVG lesions more often lead to strut penetration into the necrotic 
core, which may delay healing and perpetuate inflammation, com-
pared with stents implanted into native coronary artery lesions 
resulting in an increased risk for thrombotic occlusions23. In addi-
tion, neoatherosclerotic changes have been observed as early as one 
year after stent implantation in SVG lesions, which is more prema-
ture than observed in native coronary artery lesions. Although the 
prevalence of neoatherosclerosis within DES-treated SVG lesions 
has not been assessed to date, pathology studies suggest that neo-
atherosclerosis is an important mechanism contributing to resteno-
sis during long-term follow-up, providing a potential explanation 
for the high TLR rates observed in this study beyond one year.
Very late stent thrombosis is one of the major concerns with the 
use of early-generation DES; however, the use of EES was associated 
with a substantial reduction in an all-comers patient population9,10. In 
the present study, there were no differences among the three stent 
platforms. However, event rates and patient population were small, 
precluding further exploration of differences among devices.
Limitations
The present study has to be interpreted in view of the following limi-
tations. First, this study was not specially designed to compare the 
safety and efficacy of newer-generation EES with early-generation 
DES in SVG lesions. The data are derived from a non-randomised, 
observational cohort. Second, we lack information regarding the 
diameter of SVG lesions, the use of distal protection devices, and the 
age of SVGs at the time point of the intervention. Third, patients were 
enrolled during different time periods and advances in interventional 
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techniques (e.g., more frequent post-dilatation) may have impacted 
on results. In addition, the follow-up period differed among the three 
treatment groups. However, we employed statistical methodologies 
to present adjusted analyses by employing inverse probability of 
treatment weights and the reporting of cumulative incidence rates. 
Finally, the sample size of this study is small; larger patient popula-
tions are needed to address more definitively the value of newer-
generation DES in SVG lesions.
Conclusions
Among patients undergoing PCI for SVG lesions, newer-genera-
tion EES provide similar safety and efficacy compared to early-
generation SES and PES during long-term follow-up. The high 
rates of adverse events among patients with SVG disease are related 
to disease progression of treated and untreated SVG segments.
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